Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 11:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Phototherapy lights Clear all
Active, not recruiting Not applicable Interventional

Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions

NCT02802553
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Smart Goggle, Cardio-Green, SPY Elite Imaging system, Quest near-infrared (NIR) Imaging system, PDE Imaging system, Gamma probe, Blue Dyes
Device · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Not applicable Interventional Results available

180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma

NCT02628223
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension, Glaucoma, Open Angle, Pseudo-exfoliative, Pigment Dispersion Syndrome, Glaucoma
Interventions
Selective Laser Trabeculoplasty, Neodymium:Yttrium Aluminum Garnet (YAG) laser
Procedure · Device
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Wilmington, Delaware • Thorndale, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)

NCT00933543
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Visonac PDT (MAL PDT), Vehicle cream (placebo), PDT
Drug · Procedure
Lead sponsor
Photocure
Industry
Eligibility
9 Years to 35 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Naperville, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Phase 3 Interventional

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

NCT00306800
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy with methyl aminolevulinate cream
Procedure
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
St. Petersburg, Florida • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 24, 2026, 11:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280
View directory record Official record
Conditions
Opioid Use Disorder, Sleep Disturbance
Interventions
Post-Illumination Pupillary Response (PIPR), Polysomnography, Multiple Sleep Latency Test, Ecological Momentary Assessments, Actigraphy, DLMO, Melatonin Suppression Test
Other · Behavioral · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

Corneal Collagen Cross-Linking for Ectasia (CXL)

NCT00674661
View directory record Official record
Conditions
Ectasia
Interventions
riboflavin ophthalmic solution, UVA Irradiation
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
14 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Artificial Sunlight on Human Sleep and Circadian Rhythms

NCT03636360
View directory record Official record
Conditions
Sleep, Circadian Dysregulation, Mood
Interventions
Light
Device
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 24, 2026, 11:45 AM EDT
Recruiting Phase 3 Interventional

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

NCT06699212
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
Combination Product · Biological · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Phase 1 Interventional

Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities

NCT02240498
View directory record Official record
Conditions
Abscess
Interventions
Methylene Blue, 20% I.V. Fat Emulsion, Insertion of optical fiber, Laser illumination, 5 minutes, Laser illumination, 10 minutes, Laser illumination, 15 minutes, Laser illumination, 20 minutes, Laser illumination, 25 minutes, Laser illumination, 30 minutes, Optical spectroscopy measurement
Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 24, 2026, 11:45 AM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

NCT03090412
View directory record Official record
Conditions
Stage I Oral Cavity Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma
Interventions
HPPH, Laboratory Biomarker Analysis, Photodynamic Therapy, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne

NCT00594425
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Methyl aminolevulinate (MAL) PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
15 Years to 40 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
San Diego, California • Vallejo, California • Naperville, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Sep 24, 2026, 11:45 AM EDT
Recruiting Not applicable Interventional

Modifying the Inpatient Environment to Reduce Delirium in Older Adults

NCT06736951
View directory record Official record
Conditions
Delirium, Sleep Hygiene
Interventions
MMSH (Multi-Modal Sleep Hygiene) Bundle
Other
Lead sponsor
Farhaan S. Vahidy
Other
Eligibility
70 Years and older
Enrollment
10,890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Baytown, Texas • Houston, Texas • Sugarland, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 24, 2026, 11:45 AM EDT
Not listed Phase 3 Interventional

Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic Disorders

NCT03858036
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Ricrolin+, VEGA UV-A system
Drug · Device
Lead sponsor
Center for Sight, Sacramento, CA
Other
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Sep 24, 2026, 11:45 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Not applicable Interventional

Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3

NCT06595030
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Active Lighting Intervention, Control Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Menands, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 24, 2026, 11:45 AM EDT
Completed No phase listed Observational

Wound Necrosis in Lower Extremity Surgery

NCT03351387
View directory record Official record
Conditions
Extremity Lower Wounds
Interventions
SPY Intra-operative Angiography
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 24, 2026, 11:45 AM EDT
Withdrawn Not applicable Interventional

Integrated Imaging System for In Vivo Visualization of Free Flap Perfusion Using Indocyanine Dye

NCT03625765
View directory record Official record
Conditions
Breast Reconstruction
Interventions
SmartGoggles
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 24, 2026, 11:45 AM EDT
Not yet recruiting Phase 2 Interventional

Deep Sleep in Older Adults

NCT07316153
View directory record Official record
Conditions
Insomnia, Insomnia Chronic
Interventions
CBT-I-IoT-AI, SleepEZ CBTi, Sleep Hygiene IoT
Behavioral
Lead sponsor
Proactive Life Inc
Industry
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influence of Nocturnal Light Exposure on the Impairment of Glucose Tolerance Induced by Chronic Sleep Restriction

NCT04868539
View directory record Official record
Conditions
Glucose Intolerance, Sleep Deprivation, Sleep
Interventions
Sleep Restriction with ALAN first, then Sleep Restriction without ALAN, Sleep Restriction without ALAN first, then sleep restriction with ALAN
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 24, 2026, 11:45 AM EDT
Recruiting Not applicable Interventional

The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

NCT03482245
View directory record Official record
Conditions
Pneumonia, Necrotizing Soft Tissue Infection, Intraabdominal Infections, Infection Joint
Interventions
Blue Light
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Not applicable Interventional Results available

Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

NCT02461225
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Erchonia® FX-635™, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 24, 2026, 11:45 AM EDT
Active, not recruiting Not applicable Interventional

Cycled Phototherapy

NCT03927833
View directory record Official record
Conditions
Hyper Bilirubinemia, Premature Infant
Interventions
Phototherapy lights
Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
22 Weeks to 27 Weeks
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 24, 2026, 11:45 AM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 24, 2026, 11:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dose-dependent Impact of Daytime Lighting on Evening Responses to Light

NCT04882280
View directory record Official record
Conditions
Sleep
Interventions
Light
Behavioral
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 24, 2026, 11:45 AM EDT